IP Strategy for Genetic Medicines and Biologics

Intellectual property is the single most consequential asset class for early-stage biotech. For companies developing gene therapies, gene editing technologies, RNA therapeutics, and biologics, IP determines whether you can operate freely, whether investors will fund you, and whether your competitive position will survive first contact with the market. At preclinical stage, IP portfolio strength is often the primary driver of valuation.

Yet IP strategy is where we see early-stage teams make the most expensive mistakes. Filing too late. Filing too broadly. Failing to clean chain of title before fundraising. Ignoring freedom-to-operate until a licensing negotiation forces the issue. This guide covers five core IP domains: patent strategy, patent landscape analysis, trade secrets, licensing, and IP due diligence.

Patent Strategy: What to File and When

Provisional vs. Utility Patents

Patent filing before or during initial fundraising is standard practice, as investors routinely require an IP position as a precondition for investment. The provisional application establishes a priority date at lower cost and buys a 12-month window to convert to a full utility application. A weak provisional that lacks enabling disclosure is worse than no provisional at all, because the priority date it establishes may not hold up under scrutiny.

File a strong provisional with sufficient experimental detail to support your claims, then use the 12-month conversion window strategically to generate additional supporting data. For gene therapy and RNA therapeutics, this means including sequence data, in vitro functional data, and preliminary in vivo proof-of-concept if available.

Claim Architecture After Amgen v. Sanofi

The 2023 Supreme Court decision in Amgen Inc. v. Sanofi transformed biologics patent claiming. The Court held unanimously that "the more a party claims, the broader the monopoly it demands, the more it must enable." Broad genus claims covering entire classes of antibodies, vectors, or nucleic acid constructs are now extremely difficult to sustain.

The practical response is a nested claim strategy: start with narrow, data-supported composition-of-matter claims for your specific molecule or construct, then layer method-of-use, formulation, and manufacturing process claims around them. For gene therapy, this means claiming your specific transgene-promoter-capsid combination rather than trying to claim all AAV vectors targeting a particular tissue.

Global Filing Strategy

The Patent Cooperation Treaty (PCT) system (158 contracting states) is the standard pathway. A PCT filing within 12 months of your provisional preserves your priority date across all member states and delays expensive national phase entry decisions until the 30/31-month mark. National phase entry costs vary significantly by jurisdiction and are substantially higher for EPO filings due to translation and validation requirements. Prioritize the US, EU (via EPO), Japan, and increasingly China for genetic medicines.

Freedom-to-Operate

FTO analysis answers one question: can you make, use, and sell your product without infringing someone else's valid patent claims? For genetic medicines, FTO is particularly complex due to overlapping platform patents (capsid, delivery, promoter, transgene, manufacturing process).

Conduct FTO at three gates: (1) before committing significant R&D spend, (2) before filing your IND, and (3) before any licensing or partnering discussion.

Patent Cost Planning

Patent costs escalate significantly as programs advance from provisional filing through prosecution, national phase entry, and maintenance. First-year costs (provisional through initial prosecution) and ongoing annual costs vary widely depending on claim complexity, number of jurisdictions, and prosecution strategy. FTO analysis costs scale with the breadth of the landscape search, from preliminary domestic searches to comprehensive global analysis. Budget planning should account for the full lifecycle, not just initial filings.

Patent Landscape: Gene Therapy, CRISPR, and RNA Therapeutics

Gene Therapy / AAV

The global gene therapy patent landscape includes approximately 145,000+ patents, with AAV carriers accounting for thousands of active patents. Any company working with AAV must map capsid patents, promoter-transgene combination patents, and manufacturing process patents as separate landscape layers.

CRISPR / Gene Editing

The CRISPR patent landscape remains among the most complex and contested in all of biotech, with approximately 1,000-2,000 new patent families added annually in recent years. The foundational dispute between the Broad Institute and UC Berkeley continues through the courts. For companies using CRISPR, the licensing landscape is navigable but requires careful attention to which patents cover your specific application and delivery approach.

RNA Therapeutics / LNP

The RNA therapeutics landscape is defined by Ionis Pharmaceuticals (ASO chemical modifications) and Alnylam Pharmaceuticals (RNAi applications). The LNP delivery landscape is a patent thicket involving Moderna, BioNTech/Pfizer, Acuitas Therapeutics, and Arbutus Biopharma, with litigation and settlements continuing to reshape the landscape. LNP patents cover ionizable lipids, lipid ratio formulations, manufacturing processes, and combinations, making FTO analysis particularly complex.

Searching and Mapping Tools

• Free tools: Google Patents (120M+ patent publications), Espacenet (140M+ patent documents), The Lens (125M+ patent records with biological sequence search)
• Commercial platforms: PatSnap (AI-powered semantic mapping), Questel Orbit (molecular structure search), DrugPatentWatch (pharmaceutical-specific, linked to approved drugs)

Trade Secrets: The Most Undervalued IP Asset

Trade secrets protect what patents cannot or should not cover: manufacturing know-how, proprietary assay conditions, cell culture parameters, formulation details, preclinical datasets, and process optimizations. In cell and gene therapy, trade secrets are used more extensively than for traditional biologics due to the complex manufacturing steps involved.

Patent vs. Trade Secret Decision Framework

A four-factor analysis considering: (1) business model, (2) nature of the innovation, (3) detectability and reverse-engineering risk, and (4) competitive landscape. The standard practice for biologics and gene therapies is a hybrid strategy: patent the product while trade-secreting the manufacturing process.

Legal Framework

The Defend Trade Secrets Act of 2016 (DTSA) created a federal civil cause of action for trade secret misappropriation, including civil seizure provisions and a broad definition encompassing manufacturing methods and clinical data. For companies outsourcing to CMOs, contractual safeguards and information compartmentalization are essential supplements to DTSA protection.

Protection Essentials

Effective trade secret programs start with a comprehensive audit of what you have, followed by role-based access controls, robust employment and consulting agreements (CIIAAs), secure collaborative research protocols, and formalized exit procedures. For companies outsourcing to CMOs and CROs, the contractual and operational safeguards around shared information are particularly critical, and are often the weakest link in early-stage trade secret protection.

Licensing: In-Licensing, Out-Licensing, and Deal Economics

In-Licensing Foundations

Most genetic medicines companies in-license at least one foundational technology. University technology transfer offices are the most common source. Under the Bayh-Dole Act, universities retain IP from federally funded research and license it to industry. University license terms are generally more founder-friendly than industry-to-industry deals, but they come with diligence milestones, sublicensing restrictions, and government march-in rights.

Deal Economics

Licensing deal structures in biotech typically include upfront payments, development and commercial milestone payments, and running royalties on net sales. The specific economics vary enormously based on stage of development, competitive dynamics, exclusivity scope, and the strategic importance of the technology. Early-stage university licenses are structured very differently from industry-to-industry platform deals, and understanding the benchmarks for your specific situation is critical to negotiating effectively.

Watch for reach-through royalties on downstream products developed using a licensed research tool. These create significant long-term cost burdens through royalty stacking. NIH guidelines discourage reach-through royalties for government-funded research tools.

IP Due Diligence: What Investors Evaluate

IP due diligence is the most technically intensive component of biotech investment evaluation. VCs and pharma BD teams assess six dimensions:

• Chain of title: Does the company actually own its IP? This is the #1 diligence killer. Clean assignment chains from inventors to the company, with no gaps or ambiguities.
• Patent scope and quality: Composition-of-matter claims, claim breadth relative to competitive landscape, prosecution history.
• Freedom to operate: Can the company commercialize without infringing third-party patents? What are the known risks and mitigation strategies?
• Remaining patent term: How much exclusivity protection exists? Is there patent term extension potential?
• Competitive positioning: Where does the IP portfolio sit relative to competitors? What is the white space?
• Trade secret protection: Does the company have adequate internal controls? CIIAAs in place? CMO/CRO agreements with proper IP provisions?

Common Due Diligence Red Flags

• Missing or incomplete inventor assignments
• University license with unresolved march-in risk
• No FTO analysis conducted
• Broad claims that may not survive post-Amgen v. Sanofi scrutiny
• Key technology dependent on a single patent nearing expiration
• No trade secret protection program in place
• Reach-through royalties creating stacking risk